Outsourcing

Articles

Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.

Piramal Pharma Solutions Expands and Upgrades UK Manufacturing Facilities

China-based CDMO Asymchem acquires US-based chemical technology company Snapdragon. 

Asymchem Acquires Snapdragon Chemistry

Meg Rivers is the former senior editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

In this episode of Drug Digest, Chris Spivey, editorial director, and Meg Rivers, senior editor, dive into APIs, excipients, and formulation advances, specifically pairing the right APIs and excipients for optimizing formulations.

Drug Digest: Pairing the Right APIs and Excipients for Optimizing Formulations

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Cytiva Provides Arranta Bio with Single-Use Manufacturing Platform for mRNA Products

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

Industry experts share their top outsourcing tips from both the perspective of companies offering outsourcing services as well as for companies looking to outsource.

What Outsourcing Partners Wish You Knew

James Park is executive vice-president and managing director of the Global Sales Center at Samsung Biologics.

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

CDMOs offer expertise and capacity for spray drying.

Spray Drying Finds Growing Use for ASDs

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal 

Cyxone has appointed a European CDMO to scale-up and produce the active ingredient of its T20K drug candidate.

Contract Manufacturing, General